Eli Lilly and Co. expressed disappointment at the CMS' decision that stopped short of fully endorsing Amyvid, a PET beta-amyloid imaging drug used to assess Alzheimer's disease. The company said limiting access to Amyvid is "contrary to expert opinion" and violates the National Alzheimer's Project Act, which aims to develop new ways to diagnose and treat patients with the disease. "We will be evaluating all available options to ensure patients and physicians can gain access to this innovative diagnostic tool as soon as possible," a company statement said.

Related Summaries